Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05059327 · ClinicalTrials.gov registry record · Phase 2
Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC
A Phase 2 study, sponsored by Noema Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT05059327: Completed Phase 2 study, sponsored by Noema Pharma.
NCT05059327 is a Phase 2 study that has completed, run by Noema Pharma. The registered enrollment target is 61 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05059327, a Phase 2 study, has completed, sponsored by Noema Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The study intends to show that basimglurant (NOE-101) provides effective seizure control in children, adolescents and young adults with Tuberous Sclerosis Complex (TSC).
Interventions
- DRUG Basimglurant with crossover to Placebo
- DRUG Placebo with crossover to Basimglurant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2022-03-03 |
| Est. Completion | 2025-04-28 |
| Phase | Phase 2 |
What the finished NCT05059327 record still lists
NCT05059327 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 2 interventions - of which Basimglurant with crossover to Placebo is the first listed.
NCT05059327 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05059327 about?
NCT05059327 is a clinical study titled "Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC". The study intends to show that basimglurant (NOE-101) provides effective seizure control in children, adolescents and young adults with Tuberous Sclerosis Complex (TSC).
What is the current status of trial NCT05059327?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2022-03-03. Estimated completion is 2025-04-28.
What interventions are being tested in trial NCT05059327?
The interventions under investigation include: Basimglurant with crossover to Placebo (DRUG), Placebo with crossover to Basimglurant (DRUG).
Who is sponsoring clinical trial NCT05059327?
This trial is sponsored by Noema Pharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05059327's enrollment target sits among peer trials
61 1026th of 2000 higher than 974 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI